This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
The data that support the findings of this study are available from the corresponding author upon request.
Zhang XS, Gale RP, Huang XJ, Jiang Q. Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors? Leukemia. 2022;36:482–91.
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84.
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017;376:917–27.
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–84.
Guilhot J, Baccarani M, Clark RE, Cervantes F, Guilhot F, Hochhaus A, et al. Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood. 2012;119:5963–71.
Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041–51.
Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809–20.
Zhang XS, Gale RP, Zhang MJ, Huang XJ, Jiang Q. A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy. Leukemia. 2022;36:1336–42.
We would like to thank the following medical staffs who provided patients data: Xiaohui Suo, Weihua Zhang and Yuanjun Zheng, Lijie Yang, Zhiqiang Sun, Rongxia Wei, Jijun Wang and Lan Ma, Qingshu Zeng, Zhen Xiao, Junxia Meng and Xiaonan Zhang, Hebing Zhou, Congmeng Lin, Pengliang Xin, Yanping Ma and Xiaoyan Ge, Yujuan Yang, Yujing and Lijun Wang, Huanling Zhu, Ling Pan and Yunfan Yang, Xingxia Zhang, Hongguo Zhao and Hairong Fei, Yonghuai Feng, Linhua Yang, Xiaoyi Lv, Hai Yi and Yilan Liu, Yun Zeng, Hua Fan, Liling Zheng, Jianmin Luo, Jianhui Qiao, Luoming Hua, Shasha Zhao, Yin Sai, Ronghua Hu, Lianyu Shen, Li Ding, Fang Ye, Shunjie Wu, Min Ouyang and Meixiang Zhao, Qin Li, Liru Wang, Wangxiang Huang, Wenqian Li, Jianli Wang, Yun Li and Jing Liu. QJ acknowledges support from the National Natural Science Foundation of China (No. 81970140). RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme.
Funded, in part, by the National Nature Science Foundation of China (No. 81970140) and CAMS Innovation Fund for Medical Sciences (CIFMS) (No. 2019-I2M-5-034).
RPG is a consultant to NexImmune Inc. and Ananexa Pharma Ascentage Pharm Group, Antengene Biotech LLC, Medical Director, FFF Enterprises Inc.; partner, AZAC Inc.; Board of Directors, Russian Foundation for Cancer Research Support; and Scientific Advisory Board: StemRad Ltd.
Approved by the Ethics Committee of People’s Hospital Beijing compliant with principles of the Helsinki Declaration.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Zhang, X., Gale, R.P., Liu, B. et al. Validation of the imatinib-therapy failure model. Leukemia 37, 1166–1169 (2023). https://doi.org/10.1038/s41375-023-01875-3